Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1

Paul C. Trippier, Radhia Benmohammed, Donald R. Kirsch, Richard B. Silverman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Amyotrophic lateral sclerosis (ALS) is a debilitating and fatal neurodegenerative disease. Although the cause remains unknown, misfolded protein aggregates are seen in neurons of sporadic ALS patients, and familial ALS mutations, including mutations in superoxide dismutase 1 (SOD1), produce proteins with an increased propensity to misfold and aggregate. A structure activity relationship of a lead scaffold exhibiting neuroprotective activity in a G93A-SOD1 mouse model for ALS has been further investigated in a model PC12 cellular assay. Synthesis of biotinylated probes at the N1 nitrogen of the pyrazolone ring gave compounds (5d-e) that retained activity within 10-fold of the proton-bearing lead compound (5a) and were equipotent with a sterically less cumbersome N1-methyl substituted analogue (5b). However, when methyl substitution was introduced at N1 and N 2 of the pyrazolone ring, the compound was inactive (5c). These data led us to investigate further the pharmacophoric nature of the pyrazolone unit. A range of N1 substitutions were tolerated, leading to the identification of an N1-benzyl substituted pyrazolone (5m), equipotent with 5a. Substitution at N2 or excision of N2, however, removed all activity. Therefore, the hydrogen bond donating ability of the N2-H of the pyrazolone ring appears to be a critical part of the structure, which will influence further analogue synthesis.

Original languageEnglish (US)
Pages (from-to)6647-6650
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume22
Issue number21
DOIs
StatePublished - Nov 1 2012

Fingerprint

Pyrazolones
Mutant Proteins
Cytotoxicity
Superoxide Dismutase
Hydrogen
Hydrogen bonds
Agglomeration
Substitution reactions
Amyotrophic Lateral Sclerosis
Proteins
Bearings (structural)
Neurodegenerative diseases
Lead compounds
Mutation
Structure-Activity Relationship
Scaffolds
Neurodegenerative Diseases
Neurons
Protons
Assays

Keywords

  • Amyotrophic lateral sclerosis
  • Neuroprotection
  • Pharmacophore
  • Pyrazolone
  • Superoxide dismutase 1

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1. / Trippier, Paul C.; Benmohammed, Radhia; Kirsch, Donald R.; Silverman, Richard B.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 22, No. 21, 01.11.2012, p. 6647-6650.

Research output: Contribution to journalArticle

@article{f64e0905cc034f699b2c935d2207db9f,
title = "Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1",
abstract = "Amyotrophic lateral sclerosis (ALS) is a debilitating and fatal neurodegenerative disease. Although the cause remains unknown, misfolded protein aggregates are seen in neurons of sporadic ALS patients, and familial ALS mutations, including mutations in superoxide dismutase 1 (SOD1), produce proteins with an increased propensity to misfold and aggregate. A structure activity relationship of a lead scaffold exhibiting neuroprotective activity in a G93A-SOD1 mouse model for ALS has been further investigated in a model PC12 cellular assay. Synthesis of biotinylated probes at the N1 nitrogen of the pyrazolone ring gave compounds (5d-e) that retained activity within 10-fold of the proton-bearing lead compound (5a) and were equipotent with a sterically less cumbersome N1-methyl substituted analogue (5b). However, when methyl substitution was introduced at N1 and N 2 of the pyrazolone ring, the compound was inactive (5c). These data led us to investigate further the pharmacophoric nature of the pyrazolone unit. A range of N1 substitutions were tolerated, leading to the identification of an N1-benzyl substituted pyrazolone (5m), equipotent with 5a. Substitution at N2 or excision of N2, however, removed all activity. Therefore, the hydrogen bond donating ability of the N2-H of the pyrazolone ring appears to be a critical part of the structure, which will influence further analogue synthesis.",
keywords = "Amyotrophic lateral sclerosis, Neuroprotection, Pharmacophore, Pyrazolone, Superoxide dismutase 1",
author = "Trippier, {Paul C.} and Radhia Benmohammed and Kirsch, {Donald R.} and Silverman, {Richard B.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1016/j.bmcl.2012.08.114",
language = "English (US)",
volume = "22",
pages = "6647--6650",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "21",

}

TY - JOUR

T1 - Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant superoxide dismutase 1

AU - Trippier, Paul C.

AU - Benmohammed, Radhia

AU - Kirsch, Donald R.

AU - Silverman, Richard B.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Amyotrophic lateral sclerosis (ALS) is a debilitating and fatal neurodegenerative disease. Although the cause remains unknown, misfolded protein aggregates are seen in neurons of sporadic ALS patients, and familial ALS mutations, including mutations in superoxide dismutase 1 (SOD1), produce proteins with an increased propensity to misfold and aggregate. A structure activity relationship of a lead scaffold exhibiting neuroprotective activity in a G93A-SOD1 mouse model for ALS has been further investigated in a model PC12 cellular assay. Synthesis of biotinylated probes at the N1 nitrogen of the pyrazolone ring gave compounds (5d-e) that retained activity within 10-fold of the proton-bearing lead compound (5a) and were equipotent with a sterically less cumbersome N1-methyl substituted analogue (5b). However, when methyl substitution was introduced at N1 and N 2 of the pyrazolone ring, the compound was inactive (5c). These data led us to investigate further the pharmacophoric nature of the pyrazolone unit. A range of N1 substitutions were tolerated, leading to the identification of an N1-benzyl substituted pyrazolone (5m), equipotent with 5a. Substitution at N2 or excision of N2, however, removed all activity. Therefore, the hydrogen bond donating ability of the N2-H of the pyrazolone ring appears to be a critical part of the structure, which will influence further analogue synthesis.

AB - Amyotrophic lateral sclerosis (ALS) is a debilitating and fatal neurodegenerative disease. Although the cause remains unknown, misfolded protein aggregates are seen in neurons of sporadic ALS patients, and familial ALS mutations, including mutations in superoxide dismutase 1 (SOD1), produce proteins with an increased propensity to misfold and aggregate. A structure activity relationship of a lead scaffold exhibiting neuroprotective activity in a G93A-SOD1 mouse model for ALS has been further investigated in a model PC12 cellular assay. Synthesis of biotinylated probes at the N1 nitrogen of the pyrazolone ring gave compounds (5d-e) that retained activity within 10-fold of the proton-bearing lead compound (5a) and were equipotent with a sterically less cumbersome N1-methyl substituted analogue (5b). However, when methyl substitution was introduced at N1 and N 2 of the pyrazolone ring, the compound was inactive (5c). These data led us to investigate further the pharmacophoric nature of the pyrazolone unit. A range of N1 substitutions were tolerated, leading to the identification of an N1-benzyl substituted pyrazolone (5m), equipotent with 5a. Substitution at N2 or excision of N2, however, removed all activity. Therefore, the hydrogen bond donating ability of the N2-H of the pyrazolone ring appears to be a critical part of the structure, which will influence further analogue synthesis.

KW - Amyotrophic lateral sclerosis

KW - Neuroprotection

KW - Pharmacophore

KW - Pyrazolone

KW - Superoxide dismutase 1

UR - http://www.scopus.com/inward/record.url?scp=84867582469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867582469&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2012.08.114

DO - 10.1016/j.bmcl.2012.08.114

M3 - Article

C2 - 23021992

AN - SCOPUS:84867582469

VL - 22

SP - 6647

EP - 6650

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 21

ER -